Table 3.
Quality and risk of bias assessment for randomized studies
| Wang Y. 2012 [24] | Zhao L. 2015 [74] | Yang P. 2012 [76] | Leibowitz D. 2012 [77] | Schmid J.P. 2013 [78] | Yang P. 2013 [79] | |
|---|---|---|---|---|---|---|
| Random sequence generation | high risk | low risk | high risk | high risk | high risk | high risk |
| Allocation concealment | high risk | high risk | high risk | high risk | high risk | high risk |
| Blinding of participants | high risk | low risk | high risk | low risk | low risk | high risk |
| Blinding of personnel who provide CSWT treatment | high risk | high risk | high risk | high risk | high risk | high risk |
| Blinding of outcome assessment | unclear risk | high risk | high risk | high risk | high risk | high risk |
| Incomplete outcome data | high risk | high risk | low risk | high risk | high risk | low risk |
| Selective reporting | low risk | low risk | low risk | low risk | low risk | low risk |
| Blinding of CWST procedure | high risk | low risk | high risk | low risk | low risk | high risk |
| Endpoints were based on sample size calculation | high risk | high risk | high risk | high risk | high risk | high risk |
| Complete testing in both groups | low risk | low risk | low risk | low risk | low risk | low risk |
CSWT cardiac shock wave therapy